.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
UBS
Daiichi Sankyo
Queensland Health
Citi
Boehringer Ingelheim
Express Scripts
McKinsey
Federal Trade Commission
US Department of Justice

Generated: September 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,235,627 protect, and when does it expire?


Patent ► Subscribe protects SAXENDA, VICTOZA, and XULTOPHY 100/3.6, and is included in three NDAs. There has been one Paragraph IV challenge on Victoza.

This patent has eighty-eight patent family members in twenty-three countries.

Summary for Patent: ► Subscribe

Title:Derivatives of GLP-1 analogs
Abstract:The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.
Inventor(s): Knudson; Liselotte Bjerre (Valby, DK), Huusfeldt; Per Olaf (Kobenhavn K, DK), Nielsen; Per Franklin (V.ae butted.rlose, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:10/285,079
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeYY
Novo Nordisk Inc
VICTOZA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes► Subscribe► SubscribeYY
Novo Nordisk Inc
XULTOPHY 100/3.6
insulin degludec; liraglutide
SOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark0931/96Aug 30, 1996
Denmark1259/96Nov 08, 1996
Denmark1470/96Dec 20, 1996
Denmark0263/98Feb 27, 1998
Denmark0264/98Feb 27, 1998
Denmark0268/98Feb 27, 1998
Denmark0272/98Feb 27, 1998
98610006Mar 13, 1998
Denmark0508/98Apr 08, 1998
Denmark0509/98Apr 08, 1998

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,268,343 Derivatives of GLP-1 analogs► Subscribe
8,097,698Derivatives of GLP-1 analogs► Subscribe
7,226,990Extendin derivatives► Subscribe
6,458,924 Derivatives of GLP-1 analogs► Subscribe
6,384,016 Stabilized aqueous peptide solutions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria265224► Subscribe
Austria269103► Subscribe
Austria356830► Subscribe
Austria466026► Subscribe
Austria466027► Subscribe
Austria466028► Subscribe
Australia2610599► Subscribe
Australia2610699► Subscribe
Australia2610799► Subscribe
Australia2610899► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
QuintilesIMS
Citi
Cerilliant
AstraZeneca
UBS
US Department of Justice
Federal Trade Commission
Healthtrust
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot